Abionyx Pharma
ABIONYX Pharma SA is a French pre-commercial biotech developing HDL-based biomedicines (CER-001, ABNX-100) for LCAT deficiency, sepsis, and ophthalmology, with all current revenue generated by its IRIS Pharma ophthalmology CRO subsidiary.
- Company typePublic
- Founded2005
- HeadquartersBalma, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Abionyx Pharma does
ABIONYX Pharma SA is a French publicly-traded biotech (Euronext Paris: ABNX) developing HDL-based biomedicines for indications with no approved therapy, including LCAT deficiency (a rare renal disease), sepsis, and ophthalmological conditions. Its core product is CER-001, a recombinant apoA-I HDL vector biomedicine, manufactured using a proprietary platform that combines high-performance apoA-I bioproduction with exclusive mastery of ultra-pure synthetic sphingomyelin. A March 2026 breakthrough delivered a threefold increase in sphingomyelin production yield. A second pipeline asset, ABNX-100, is referenced as an additional therapeutic candidate. The company is pursuing an EMA Marketing Authorization Application for CER-001 in LCAT deficiency targeted for early 2028, alongside a Phase 2b sepsis trial, and holds published clinical evidence from the RACERS study in BMC Medicine/Nature Springer.
The company's revenue model is bifurcated. All current consolidated revenue — EUR 4.1M in FY2025 and EUR 0.83M in Q1 2026 — is generated entirely by its wholly-owned IRIS Pharma subsidiary, a contract research organization specializing in ophthalmology that serves external pharmaceutical and biotech clients through direct enterprise engagements. The therapeutic development business (CER-001, ABNX-100) is pre-commercial and contributes zero revenue. Non-dilutive government funding (EUR 8.7M France 2030 i-Démo, ~EUR 1M Bpifrance) supplements the funding mix alongside equity (EUR 18.7M rights issue in June 2026) and non-convertible bond financing (up to EUR 14M from Fenja Capital II A/S), extending the cash runway into Q4 2028.
Go-to-market is enterprise and regulatory: the company targets institutional healthcare stakeholders, the EMA regulatory pathway, and strategic partners (e.g., SEBIA for companion diagnostics in sepsis). Distribution is pre-commercial for therapeutics and direct enterprise sales for IRIS Pharma CRO services. The company operates from Balma, France, with a headcount of 1–10 employees, and is led by CEO Cyrille Tupin, CMO Rob Scott, and CDIO Laurent Guerci.
Abionyx Pharma firmographics
Firmographics- Name
- Abionyx Pharma
- Legal name
- ABIONYX Pharma SA
- Website
- https://abionyx.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ABIONYX Pharma SA is a French pre-commercial biotech developing HDL-based biomedicines (CER-001, ABNX-100) for LCAT deficiency, sepsis, and ophthalmology, with all current revenue generated by its IRIS Pharma ophthalmology CRO subsidiary.
- Ownership category
- akta.pro rank
Abionyx Pharma industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Abionyx Pharma is headquartered
LocationHeadquarters
- HQ city
- Balma
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Abionyx Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Contract Research Services (IRIS Pharma): Revenue is generated entirely through IRIS Pharma, a contract research organization (CRO) specializing in ophthalmology. The therapeutic development business (CER-001, ABNX-100) generates no revenue as products remain in clinical development.
- Non-dilutive Government Funding: The company secures non-dilutive funding through grants and programs such as France 2030's i-Démo program (€8.7 million secured, €6.5 million remaining) and Bpifrance innovation grants (nearly €1 million for CER-001 ophthalmology development).
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Abionyx Pharma product offering
Product offeringCore offering
ABIONYX Pharma is a clinical-stage biotech developing HDL-based biomedicines, principally lead candidate CER-001 (a recombinant apoA-I biomedicine) for LCAT deficiency, sepsis, and ophthalmological indications, along with ABNX-100 as a second pipeline candidate. The company complements its therapeutic development business with its wholly-owned IRIS Pharma subsidiary, a contract research organization that delivers ophthalmology research services and currently generates all of the group's consolidated revenue.
Product overview
ABIONYX Pharma is a new-generation biotech company developing innovative therapies through two main drug candidates: CER-001 (a HDL-based biomedicine for LCAT deficiency, sepsis, and ophthalmology) and ABNX-100. The company also operates through its IRIS Pharma subsidiary, a contract research organization providing ophthalmology research services. The product portfolio centers on HDL vectors used for targeted drug delivery in renal, ophthalmological, and rare diseases where no effective treatment exists.
Differentiator
Problem solved
Functional benefit
Products and services
- CER-001 CER-001 is ABIONYX Pharma's lead biomedicine drug candidate, based on a recombinant apoA-I HDL vector technology, being developed for the treatment of LCAT (Lecithin-Cholesterol Acyltransferase) deficiency, sepsis, and ophthalmological indications. It is targeted at patients with rare and unmet medical needs, and is being progressed toward a Marketing Authorization Application with the EMA targeted for early 2028.
- ABNX-100 ABNX-100 is a pipeline drug candidate of ABIONYX Pharma, referenced alongside CER-001 as one of the company's key therapeutic assets for innovative applications leveraging the company's HDL-based bioproduct platform.
- IRIS Pharma CRO services IRIS Pharma is the wholly-owned contract research organization (CRO) subsidiary of ABIONYX Pharma, specializing in ophthalmology research services for pharmaceutical and biotech companies. It generated all of ABIONYX's consolidated revenue (€4.1 million in FY2025) and had €2.6 million in business secured for FY2026.
Quantifiable outcome
- Threefold increase in sphingomyelin production yield for CER-001 manufacturing
- +2 more outcomes
Companies that use Abionyx Pharma
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Abionyx Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Abionyx Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SEBIAcoreABIONYX Pharma and SEBIA announced an exclusive global strategic partnership focused on developing new diagnostic tests for early detection and monitoring of sepsis. The partnership aims to improve sepsis management through combined expertise in lipid biology, clinical studies, and blood sample analysis.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Abionyx Pharma competitors and assessment
Company assessmentBroad incumbents
- Esperion Therapeutics: Esperion commercializes bempedoic acid (Nexletol/Nexlizet) for LDL cholesterol lowering, addressing lipid-related cardiovascular disease with a similar therapeutic-area focus to ABIONYX. As a small-cap public commercial-stage peer, it offers a comparable go-to-market benchmark for lipid-targeting therapeutics.
- Recordati Rare Diseases: Recordati's rare diseases division commercializes treatments for rare metabolic and endocrine disorders globally. As an established rare-disease commercial player, it offers a comparable commercialization model and potential partner for CER-001 in LCAT deficiency upon EMA approval.
- CSL Behring: CSL Behring developed CSL112, an apoA-I infusion therapy very similar in mechanism to CER-001, for cardiovascular indications. It is a major plasma-derived therapeutics incumbent with global commercialization infrastructure, providing both a technology comparable and a precedent (the AEGIS-II Phase 3 outcome) for ABIONYX's HDL-mimetic approach.
- Sobi (Swedish Orphan Biovitrum): Sobi is a Swedish specialty biopharma focused on rare diseases, with a portfolio spanning hematology, immunology, and specialty therapeutics. It represents a potential commercialization partner or acquisition counterparty for ABIONYX's rare-disease pipeline, particularly for European orphan drug launches.
Direct peers
- Ionis Pharmaceuticals: Ionis is a leader in antisense oligonucleotide therapies for serious and rare diseases, with multiple approved products (e.g., Waylivra, Tegsedi). Its rare-disease platform focus, lipid targets, and Phase 2-3 pipeline profile closely parallel ABIONYX's specialty biotech model targeting LCAT deficiency and rare renal/ophthalmology indications.
Emerging players
- Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapies for rare diseases, leveraging a targeted-delivery platform. Its platform-based approach to delivering therapeutics to specific tissues parallels ABIONYX's HDL vector delivery concept, making it a useful comparator for technology-driven rare-disease biotechs.
- Madrigal Pharmaceuticals: Madrigal developed Rezdiffra, the first FDA-approved therapy for MASH/NASH, addressing a rare metabolic liver disease with no prior approved options. Comparable as a specialty biotech that achieved commercial approval in a previously untreated rare metabolic indication, similar to ABIONYX's LCAT deficiency strategy.
- Travere Therapeutics: Travere develops therapies for rare kidney diseases (e.g., Filspari for IgA nephropathy), making it a direct comparable to ABIONYX's LCAT deficiency renal focus. It provides a benchmark for small-cap rare renal disease biotechs progressing from clinical to commercial stages.
- CymaBay Therapeutics: CymaBay developed seladelpar (Livdelzi) for primary biliary cholangitis, a rare autoimmune liver disease. Similar to ABIONYX, it is a small public clinical-to-commercial biotech that targeted a rare disease with no effective existing treatment.
- Akari Therapeutics: Akari is a clinical-stage biotech developing therapies for rare autoimmune and inflammatory diseases, including nomacopan for conditions with high unmet need. Comparable to ABIONYX as a small-cap public rare-disease biotech with limited headcount and a single-platform therapeutic pipeline.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Abionyx Pharma social profiles
Digital presenceAbionyx Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abionyx Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Abionyx Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Abionyx Pharma funding detail
Funding detailFunding overview
Funding rounds8 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abionyx Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abionyx Pharma
What does Abionyx Pharma do?
ABIONYX Pharma is a clinical-stage biotech developing HDL-based biomedicines, principally lead candidate CER-001 (a recombinant apoA-I biomedicine) for LCAT deficiency, sepsis, and ophthalmological indications, along with ABNX-100 as a second pipeline candidate. The company complements its therapeutic development business with its wholly-owned IRIS Pharma subsidiary, a contract research organization that delivers ophthalmology research services and currently generates all of the group's consolidated revenue.
Is Abionyx Pharma a public or private company?
Abionyx Pharma is a public company. It is classified as public and is currently operating.
When was Abionyx Pharma founded?
Abionyx Pharma was founded in 2005. It employs 1 to 10 people.
Where is Abionyx Pharma based?
Abionyx Pharma is headquartered in Balma, France, in the Europe region.
How does Abionyx Pharma make money?
Two revenue lines are on record. Contract Research Services (IRIS Pharma) is the primary driver. The others are non-dilutive Government Funding.
Who are Abionyx Pharma's main competitors?
Broad incumbents on record are Esperion Therapeutics, Recordati Rare Diseases, CSL Behring and Sobi (Swedish Orphan Biovitrum). Ionis Pharmaceuticals is listed as a direct peer. Emerging players are Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, Travere Therapeutics, CymaBay Therapeutics and Akari Therapeutics.
Does Abionyx Pharma have an API?
No public API is recorded for Abionyx Pharma.
What industry is Abionyx Pharma in?
Abionyx Pharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 325412 and its SIC code is 2834.